FindTrial
Sign In

Dilanubicel

BIOLOGICAL2 trials

Sponsors

Fred Hutchinson Cancer Center

Conditions

Acute Biphenotypic LeukemiaAcute Erythroid LeukemiaAcute Lymphoblastic LeukemiaAcute Megakaryoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveHIV InfectionHematopoietic and Lymphoid Cell Neoplasm

Phase 2

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Active, not recruitingNCT03399773
Fred Hutchinson Cancer CenterAcute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive +3
Start: 2022-05-10End: 2027-04-02Updated: 2026-07-10
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
TerminatedNCT04083170
Fred Hutchinson Cancer CenterAcute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia +8
Start: 2022-10-06End: 2022-11-30Updated: 2025-01-01